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Summary
Sox9 and the closely related factor Sox10 are essen-
tial for the formation of neural crest precursor cells,
and play divergent roles in the process by which
these cells are subsequently directed to form specific
derivatives. These group E Sox factors have also
been implicated in the development of the vertebrate
inner ear. Despite their importance, however, the
mechanisms that allow SoxE proteins to regulate
such a diverse range of cell types have remained
poorly understood. Here we demonstrate that during
vertebrate development, the activities of individual
SoxE factors are well conserved and are regulated
by SUMOylation. We show that SoxE mutants that
cannot be SUMOylated, or that mimic constitutive
SUMOylation, are each able to mediate a subset of
the diverse activities characteristic of wild-type SoxE
proteins. These findings provide important mecha-
nistic insight into how the activity of widely deployed
developmental regulatory proteins can be directed to
specific developmental events.
Introduction
Sox proteins are high mobility group (HMG) family tran-
scription factors that regulate diverse developmental
processes (Wegner, 1999). The Sox family is divided
into subgroups A–J that possess highly homologous
HMG-type DNA binding domains but share little overall
homology outside of this region (Bowles et al., 2000).
All Sox proteins possess transcriptional activation do-
mains; however, they bind DNA with low affinity, and
are thought to require DNA binding cofactors to stabi-
lize their interactions with DNA (Kamachi et al., 2000).
Several reports have now identified partner proteins
that can interact with Sox family members in order to
synergistically activate transcription (Bondurand et al.,
2000; Lang and Epstein, 2003). Members of Sox group
E, comprised of Sox8, Sox9, and Sox10, are further
characterized by the presence of two conserved re-
gions (termed E1 and E2) that have been proposed to
be protein-protein interaction domains (Bowles et al.,
2000).
SoxE factors have emerged as important regulators
of the neural crest, a population of migratory, tissue-
invasive stem cells that plays a central role in the devel-
opment of the vertebrate body plan. Neural crest cells
migrate extensively, populate diverse regions through-*Correspondence: clabonne@northwestern.eduout the embryo, and give rise to a wide range of deriva-
tives that includes most of the neurons and glia of the
peripheral nervous system (PNS), melanocytes, and
craniofacial cartilage. At neural plate stages, Sox9 and
Sox10 are expressed by all neural crest precursor cells,
although the expression of Sox9 precedes that of Sox10
(Aoki et al., 2003; Lee et al., 2004). Later, expression of
these two factors in neural crest derivatives becomes
nonoverlapping, with Sox9 expression maintained in
cells contributing to facial cartilage and Sox10 expres-
sion restricted to presumptive melanoblasts and glia
(Spokony et al., 2002; Aoki et al., 2003; see Figure S1
in the Supplemental Data available with this article on-
line). In vivo, Sox9 and Sox10 likely play divergent roles
in the transcriptional control of these different fates
(Southard-Smith et al., 1998; Britsch et al., 2001; Stolt
et al., 2002); however, the extent to which this is due to
any distinct activities possessed by these factors has
remained unclear.
In Xenopus, morpholino-mediated depletion of either
Sox9 or Sox10 leads to a loss of neural crest precursor
formation, while overexpression of Sox9 or Sox10 can
lead to expansion of the neural crest progenitor domain
(Spokony et al., 2002; Aoki et al., 2003; Honore et al.,
2003). Thus, by the criteria of their effects on neural
crest precursor formation, these two closely related
SoxE factors appear to have similar activities. However,
it has been reported that overexpression of Sox10 but
not Sox9 induces melanocyte formation (Aoki et al.,
2003), indicating that each of these factors may also
possess some distinct activities. Studies using a num-
ber of model organisms have also implicated SoxE fac-
tors in inner ear development (Watanabe et al., 2000;
Liu et al., 2003; Saint-Germain et al., 2004). In Xenopus,
Sox9 is the earliest marker of the newly induced otic
placode, which will give rise to the inner ear, and mor-
pholino-mediated depletion of Sox9 leads to a failure
of inner ear formation (Saint-Germain et al., 2004). The
effects of upregulating SoxE activity on inner ear devel-
opment have yet to be reported.
Given their overlapping expression patterns and pro-
posed roles in neural crest precursor formation, neural
crest lineage diversification, and otic placode forma-
tion, it seemed possible that individual SoxE factors
might possess some divergent activities, and that the
complement of SoxE factors expressed in a cell might
play an instructive role in dictating that cell’s fate. To
test this hypothesis, we expressed Sox9 or Sox10 in
early Xenopus embryos and compared and contrasted
their activities. We found that each factor could direct
the formation of neural crest precursors and the devel-
opment of a range of neural crest derivatives, and we
detected no differences in the activities of Sox9 and
Sox10 in these assays. Moreover, we found that misex-
pression of Sox9 or Sox10 frequently resulted in the
formation of enlarged or ectopic otocysts, demonstrat-
ing that both factors are potent effectors of inner ear
formation. A central question in developmental biology
is how factors with conserved activity can mediate very
different functional outcomes when expressed in dif-
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which SoxE proteins might be regulated such that they
can direct development of diverse cell types, we car-
ried out a yeast two-hybrid screen that identified
SUMO-1 and UBC9 as SoxE-interacting proteins. We
report here that the SUMOylation state of SoxE proteins
plays a key role in regulating the function of these fac-
tors during neural crest and inner ear development. Our
findings suggest a novel mechanism by which the ac-
tivity of these widely deployed developmental regula-
tory proteins might be directed to specific develop-
mental events.
Results
Sox9 and Sox10 Have Equivalent Effects on Neural
Crest Formation
Although Sox9 and Sox10 have recently emerged as
key determinants of both neural crest and inner ear de-
velopment, the extent to which SoxE factors play func-
tionally equivalent roles in these processes has been
less clear. We therefore expressed these factors in early
Xenopus embryos and compared their ability to influ-
ence neural crest and inner ear fates. To control for
dosage-dependent effects, epitope-tagged forms of
both Sox9 and Sox10 were generated. The activities of
the tagged and untagged forms of each protein were
compared, and the epitope tags were found to have no
effect on function (data not shown). Experiments di-
rectly comparing Sox9 and Sox10 activity were carried
out using the epitope-tagged factors, and protein ex-
pression levels were monitored via Western blots.
mRNA encoding epitope-tagged Sox9 or Sox10 was in-
jected into one cell of two-cell stage Xenopus embryos,
and the injected embryos were allowed to develop to
neurula stages, when the effects on neural crest precur-
sor cells could be assayed by in situ hybridization.
β-galactosidase mRNA was coinjected as a lineage
tracer, and the uninjected side of the embryo served as
a control for normal development.
We found that both Sox9 and Sox10 were able to
increase the formation of neural crest precursor cells,
as evidenced by expanded expression of markers such
as Slug and Sox9 (Figures 1A–1D), consistent with pre-
vious reports (Aoki et al., 2003; Honore et al., 2003).
Significantly, however, we also noted that neural crest
markers were sometimes inhibited in Sox9- and Sox10-
injected embryos. For example, in an experiment in
which most embryos showed expanded expression of
neural crest markers, we also noted embryos in which
expression of the same markers had been inhibited
(Figures 1E and 1F) (Sox9-injected: 75% increased,
10% decreased, n = 47; Sox10-injected: 68% increased,
8% decreased, n = 38). This suggested that in the em-
bryos showing a decrease, Sox9 or Sox10 activity
might have led to the formation of some other cell type
at the expense of neural crest precursors. When in the
same experiment 5-fold higher levels of Sox9 or Sox10
were expressed, this inhibition of neural crest precursor
formation was noted more frequently than at lower
doses (Sox9-injected: 45% increased, 34% decreased,
n = 29; Sox10-injected: 40% increased, 45% decreased,
n = 40). Importantly, we observed no differences in the
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ibilities of Sox9 and Sox10 to expand or inhibit the for-
ation of neural crest precursor cells. Moreover, the
bservation that the differences in these phenotypes
ere not fully dose dependent suggested the possi-
ility that the activity of SoxE proteins might be dynam-
cally regulated, perhaps by posttranslational modifi-
ation.
ox9 and Sox10 Promote Melanocyte and Glial
ormation and Inhibit Neuronal Differentiation
e next compared the ability of Sox9 and Sox10 to
irect the formation of specific neural crest derivatives.
n particular, we were interested in comparing the ef-
ects of these two proteins on development of mela-
oblasts and glia, as previous studies have suggested
hat Sox10 is an important determinant of these lin-
ages (Southard-Smith et al., 1998; Kelsh et al., 2000;
ritsch et al., 2001; Stolt et al., 2002). Sox9 and Sox10
ere expressed at levels that predominantly expand
he neural crest progenitor pool, and injected embryos
ere harvested at tailbud stages for in situ hybridiza-
ion with markers of developing melanoblasts or al-
owed to develop to stages when formation of dif-
erentiated melanocytes could be directly evaluated. In
hese experiments, we found that both Sox9 and Sox10
otently induced the formation of melanoblasts as evi-
enced by scattered ectopic cells on the embryonic
lank that expressed melanocyte markers such as
ox10, Mitf, and Trp2 (Figures 1G and 1H and data not
hown; Sox9-injected: 51% of embryos, n = 129; Sox10-
njected: 53% of embryos, n = 103), as well as by the
ormation of supernumerary melanocytes at swimming
adpole stages (see below, and data not shown).
At the stages examined in these experiments, Sox10
xpression marks three cell populations: melanoblasts,
lia, and the developing ear. In addition to numerous
ctopic melanoblasts in caudal regions, we noted dra-
atically increased Sox10 expression in cranial re-
ions. Such staining is consistent with an increased
umber of cells adopting glial and/or otic fates. To dis-
inguish between these possibilities, we examined ex-
ression of FoxD3 at stage 28, when it serves as a glial
arker (Kelsh et al., 2000; Gilmour et al., 2002). We
ound that both Sox9- and Sox10-injected embryos
howed significantly enhanced FoxD3 staining in the
ranial ganglia (Figures 1I, 1J, 1M, and 1N) (Sox9-
njected: 69% increased, n = 55; Sox10-injected: 74%
ncreased, n = 46). Together, these findings indicate
ox9 and Sox10 can both direct the formation of at
east two cell types commonly associated with Sox10
unction, melanocytes and glia.
Recent work has implicated Sox10 in the mainte-
ance of multipotency in neural crest stem cells and in
he inhibition of neuronal differentiation (Paratore et al.,
002; Kim et al., 2003). While these studies did not ad-
ress whether other SoxE factors had similar activities,
ore recent work has demonstrated that forced ex-
ression of Sox9 blocks neuronal differentiation of neu-
al crest cells in avian embryos (Cheung and Briscoe,
003). We therefore asked whether Sox9 or Sox10
ould influence the adoption of neuronal fates in Xeno-
us neural crest cells. We found that both factors inhib-
ted the differentiation of N-tubulin-expressing cells in
SoxE SUMOylation during Neural Crest Development
595Figure 1. Effects of Sox9 and Sox10 on Neural Crest Development
(A–F) In situ hybridization examining the expression of neural crest markers Sox9 (A, B, E, and F) and Slug (C and D) in Sox9- (A, C, and E)
or Sox10- (B, D, and F) injected embryos. Injection of either Sox9 or Sox10 frequently leads to an increase in neural crest precursor formation
(A–D, white arrowhead) but could also result in loss of neural crest precursor formation (E and F, white arrowhead).
(G and H) Both Sox9 and Sox10 induce the formation of supernumerary and ectopic melanocytes (black arrows).
(I–P) An increase in FoxD3-expressing glia (I versus J; M versus N) and a decrease in N-tubulin-expressing neurons in the cranial ganglia (K
versus L; O versus P) are found in Sox9- (I–L) and Sox10- (M–P) injected embryos. Light blue or red stain is the lineage tracer β-gal.the cranial ganglia, even at doses that significantly in-
creased formation of FoxD3-expressing glia in sibling
embryos (Figures 1K, 1L, 1O, and 1P) (Sox9-injected:
69% decreased, n = 49; Sox10-injected: 72% de-
creased, n = 42).
Sox9 Can Rescue Neural Crest Formation
in Sox10-Depleted Embryos
The above data demonstrate that in overexpression as-
says, Sox9 and Sox10 are functionally equivalent with
respect to their ability to mediate neural crest forma-
tion. However, these experiments do not exclude the
possibility that these factors perform equivalently in
these assays secondary to an ability to positively cross-
regulate each other’s expression. For example, the abil-
ity of Sox9 to induce pigment cells might be due to
its ability to induce expression of endogenous Sox10,
which would then initiate a program of melanocyte dif-
ferentiation. To explore this possibility, we compared
the ability of Sox9 and Sox10 to rescue neural crest
development in embryos depleted for Sox10. Embryos
injected at the eight-cell stage with morpholinos tar-
geting Sox10 show reduced or absent expression of
early neural crest markers (Figures 2A and 2B; 90% in-
hibited, n = 59). Subsequent injection of mRNA encod-
ing either Sox9 or Sox10 significantly rescued forma-
tion of neural crest progenitors in these embryos
(Figures 2C–2F; Sox9: 18% inhibited, n = 40; Sox10:
21% inhibited, n = 52). These findings confirm that
Sox10 does not have functions during neural crest pre-
cursor formation that cannot be compensated for by
Sox9. Importantly, when rescued embryos were al-
lowed to develop to tailbud stages, we found that Sox9
was still able to induce formation of ectopic melano-cytes despite Sox10 depletion (Figures 2I and 2J). This
finding demonstrates that the ability of Sox9 to direct
melanocyte formation is not secondary to an ability to
activate Sox10.
Sox9 and Sox10 Direct the Formation of Enlarged
and Ectopic Otic Vesicles
Because SoxE factors have also been implicated in otic
placode formation, we compared the effects of Sox9
and Sox10 activity on inner ear development. The con-
sequences of SoxE misexpression on the development
of this cell type have not been previously reported. We
found that injection of mRNA encoding either factor fre-
quently led to expanded expression of otocyst markers,
or “enlarged ears” (Figures 3A and 3B) (Sox9-injected:
55% enlarged, n = 94; Sox10-injected: 61% enlarged,
n = 154). Moreover, in 3%–5% of cases, Sox9- and
Sox10-injected embryos developed supernumerary
otocysts, such that between two and four distinct otic
vesicles formed on a single side of the injected embryo
(Figures 3C, 3D, and 3F). To ask whether the appear-
ance of enlarged or ectopic otic vesicles correlated
with an increase in size of the otic placode at neural
plate stages, we examined the expression of Pax8,
which is among the earliest markers of this structure
(Heller and Brandli, 1999). We found that both Sox9 and
Sox10 could expand the domain of Pax8 expression
corresponding to this placode (Figures 3G and 3H)
(Sox9-injected: 52% increased, n = 50; Sox10-injected:
48% increased, n = 62). Similarly, both factors could
mediate increased Dlx3 expression in the developing
ear at stage 25 (data not shown). Importantly, however,
Sox9 and Sox10 did not differ in their ability to induce
Developmental Cell
596Figure 2. Sox9 and Sox10 Rescue Neural
Crest Development in Sox10-Depleted Em-
bryos
Embryos injected with Sox10 morpholinos
(MO) show reduced or absent expression of
early neural crest markers such as Sox10 (A
and B) and reduced otic vesicles and cranial
neural crest (G and H). These defects could
be rescued equally well by Sox9 or Sox10
(C–F and I–L). Sox9 retains its ability to induce
ectopic melanocytes in Sox10-depleted em-
bryos (J, black arrows). Light red stain is the
lineage tracer β-gal.the formation of enlarged or ectopic ears, providing fur-
ther evidence that these factors function equivalently.
UBC9 and SUMO-1 Are SoxE-Interacting Factors
The above findings further highlight the question of
how the activity of SoxE family proteins is regulated
during the formation of diverse cell types such as the
neural crest or otic placode. To address this, we sought
to identify interacting proteins that might modify the
function of these proteins during development. We car-
ried out a yeast two-hybrid screen, using a Sox10 cDNA
truncated before the activation domain as bait and a
Xenopus gastrula stage cDNA library as prey. This
screen identified a number of SoxE-interacting pro-
teins, among which were 7 isolates of the small ubiq-
uitin-like modifier SUMO-1 and 27 isolates of the E2
SUMO-conjugating enzyme UBC9, and these factors
were also found to interact when the Sox9 N-terminus
was used as bait (Figure 4A and data not shown). To-
gether, these findings suggested the intriguing possi-
bility that SoxE activity might be regulated posttransla-
tionally via SUMOylation.
Examination of the Xenopus Sox9 and Sox10 se-
quences showed that they each possess two con-
served SUMOylation consensus sites, ΨKXE (Gill, 2004).
The first of these sites is located just N-terminal to the
E1 domain, while the second site is located within the
C-terminal activation domain (Figure 4B). Because not
all proteins containing this motif are SUMOylated in vivo
(Hay, 2005), we asked whether Xenopus Sox9 and
Sox10 are SUMOylated in Xenopus embryos. When
Sox9 or Sox10 were expressed in the presence or ab-
sence of epitope-tagged SUMO-1, Western blot analy-
sis indicated that Sox9 and Sox10 could each be
SUMOylated on two sites, and that each modification
leads to a distinct and distinguishable shift in mobility
on SDS-PAGE gels (Figures 4C and 5A). Blotting against
the myc tag on Sox9 or Sox10 following immunoprecip-
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otation of SUMO-1 (flag) confirmed that the slower mo-
ility SoxE isoforms represent SUMOylated products
Figure 3D), and SUMO modification of Sox9 has also
ecently been observed in human embryonic kidney
ells (Komatsu et al., 2004). We found that at gastrula
tages, Sox10 is SUMOylated at lysine 44 in the N ter-
inus as well as at lysine 333 in the activation domain.
n Sox9, the predominant site of SUMOylation is lysine
65 in the C terminus, although the protein can also
e SUMOylated on lysine 61. The identities of these
odified residues were confirmed by mutating one or
oth reactive lysines in the hypothesized SUMOylation
ites to arginine in order to block their SUMOylation.
xperiments in which Sox9 and Sox10 isoforms carry-
ng these lysine mutations were coexpressed with
UMO-1 in early embryos confirmed that these were
he only SUMOylation sites in these proteins (Figures
B and 5C). Consistent with this, Sox9 and Sox10 pro-
eins lacking these lysine residues no longer interact
ith SUMO-1 or UBC9 in yeast (Figure 4A). Interest-
ngly, when only a single modified lysine in Sox10 was
utated, only one of the two slower migrating Sox10
pecies was lost (Figure 5C). These findings indicate
hat the mobility differences apparent by SDS-PAGE re-
lect which site in the protein has been SUMOylated,
ather than the number of SUMO moieties appended.
UMOylation Modulates SoxE Function during
eural Crest Development
ore than half of all identified SUMO substrates are
ranscriptional regulatory proteins, and SUMOylation
an either up- or downregulate the activity of these fac-
ors (Girdwood et al., 2004). Having confirmed bio-
hemically that SoxE proteins are SUMOylated in Xeno-
us embryos, we sought to better understand how
UMOylation modulates SoxE function during neural
rest development. We initially focused these studies
n Sox9, as this protein displayed only one predomi-
SoxE SUMOylation during Neural Crest Development
597Figure 3. Sox9 and Sox10 Induce Enlarged and Ectopic Ear Struc-
tures
(A–F) In situ hybridization showing Sox10 expression in the ears of
stage 28 embryos injected with Sox9 (A and C) or Sox10 (B, D, and
F). Expression of either of these factors consistently leads to the
formation of enlarged ears (A and B, white arrows) and/or to the
formation of one or more ectopic ears (C, D, and F, black arrow-
heads).
(G and H) Increased expression of Pax8, which marks the otic plac-
ode (white arrowhead) in Sox9- (G) or Sox10- (H) injected embryos
at stage 13. Light blue or red stain is the lineage tracer β-gal.nant site of SUMO incorporation. In addition to our
loss-of-SUMOylation mutants, we generated a form of
Sox9 which had SUMO-1 fused in-frame to its C ter-
minus (Figure 6A). Such fusions have been found to
mimic the constitutively SUMOylated state of a protein
and have proven particularly useful when the native
SUMOylation site occurs near the terminus of a protein
of interest, as it is in Sox9 (Ross et al., 2002; Holmstrom
et al., 2003; Long et al., 2004). In order to facilitate inter-
pretation of these experiments, we ensured that thefused SUMO moiety would represent the only SUMO-
ylation of the protein by appending it to the double-
lysine mutant to create Sox9K61,365R/SUMO-1.
We first wished to ascertain whether the SUMO-
ylation mutants affected Sox9 protein stability, as SU-
MOylation of targeted lysines in some proteins regu-
lated by ubiquitin-dependent proteolysis results in
stabilization of those proteins (Hay, 2005). We did not
expect this to be the case for Sox9 and Sox10, how-
ever, as we have found these proteins to be very stable
when expressed in Xenopus, and have been unable to
detect their ubiquitination (data not shown). Neverthe-
less, to directly ask whether blocking SUMOylation al-
ters Sox9 stability, we expressed wild-type Sox9 and
Sox9K61,365R such that equivalent protein levels were
detected at blastula stages, and then compared the ex-
pression levels of these proteins over time. We de-
tected no difference in protein stability between wild-
type Sox9 and the double-lysine mutant (Figure 5D and
data not shown), making it unlikely that SUMOylation
regulates SoxE stability in this system.
To examine the effects of Sox9 SUMOylation on
neural crest development, mRNA encoding wild-type
Sox9, Sox9K61,365R, or Sox9K61,365R/SUMO-1 was injected
into one cell of two-cell stage embryos and effects on
neural crest precursor cells were assayed by in situ
hybridization at neurula stages. These proteins were
epitope-tagged and were expressed at equivalent
levels as determined by Western blot. When the ex-
pression of markers such as Slug and Sox10 were ex-
amined in these embryos, we found that Sox9K61,365R
and Sox9K61,365R/SUMO-1 had dramatically different ef-
fects on neural crest precursor formation. For example,
when expressed at levels at which the wild-type protein
mediates a modest increase in Sox10 expression,
Sox9K61,365R consistently induced a dramatic increase
in Sox10 expression (97% increased, n = 81). Con-
versely, Sox9K61,365R/SUMO-1 strongly inhibited Sox10
expression (97% inhibited, n = 82) (Figure 6B). Given
that wild-type SoxE proteins can both positively and
negatively influence the formation of neural crest pro-
genitors (Figure 1), these results suggest the SUMOyla-
tion state of the expressed protein may be an important
determinant of these different outcomes.
Sox9K61,365R and Sox9K61,365R/SUMO-1 were also
found to differentially affect the formation of neural
crest derivatives. For example, as with wild-type Sox9,
embryos injected with Sox9K61,365R developed numer-
ous scattered Sox10-expressing melanoblasts on the
injected side of the embryo (92%, n = 121). By contrast,
Sox9K61,365R/SUMO-1 was unable to induce ectopic
melanoblasts (0%, n = 162) (Figure 6C, black arrows).
Similarly, both wild-type Sox9 and Sox9K61,365R mediate
the formation of supernumerary differentiated melano-
cytes on the injected side of the embryo, while
Sox9K61,365R/SUMO-1 does not (Figure 6D). Also like
wild-type Sox9, we found that Sox9K61,365R could res-
cue neural crest development in Sox10-depleted em-
bryos (Figure 6E; Sox10MO: 93% inhibited, n = 28;
Sox10MO+Sox9K61,365R: 29% inhibited, n = 34). Impor-
tantly, however, Sox9K61,365R/SUMO-1 is not inactive in
these assays, as it strongly induced ectopic Sox10 ex-
pression in cranial regions (Figure 6C, white arrow-
heads). Some of this staining was consistent with en-
Developmental Cell
598Figure 4. Sox9 and Sox10 Are SUMOylated
(A) Growth of serially diluted cultures on se-
lective media showing that both Sox9 and
Sox10 (activation domain deleted) interact
with UBC9 and SUMO-1 in a yeast two-
hybrid assay. Mutation of the SUMOylation
sites prevents interaction.
(B) Schematic of SoxE protein domains.
(C) Western blot of lysates prepared from
embryos injected as noted showing modifi-
cation of Sox9 or Sox10 with SUMO-1. Ar-
rows mark reduced mobility forms resulting
from conjugation to one or more SUMO moi-
eties.
(D) Lysates from embryos injected with Sox9
or Sox10 alone, or together with SUMO-1,
were immunoprecipitated (IP) with antibod-
ies against the epitope tag in SUMO-1 (flag)
and then immunoblotted (IB) using antibod-
ies against the epitope tag on the SoxE fac-
tors (myc), confirming that more slowly mi-
grating SoxE species are SUMOylated.
Direct immunoblotting of the crude lysate
with either myc or flag antibodies served as
input control (bottom panels).otic placode formation, we compared the ability of
Figure 5. Identification of SoxE SUMOyla-
tion Sites
(A) Western blot of lysates prepared from
stage 11 embryos expressing wild-type or ly-
sine mutant Sox9 proteins. One major and
one minor SUMO-modified form of Sox9 are
noted at this stage (black and red arrows).
(B) Mutation of the reactive lysine in the
C-terminal SUMOylation site eliminates the
major modified species.
(C) Western blot of lysates prepared from
embryos expressing wild-type or lysine mu-
tant Sox10 proteins. Two SUMO-modified
forms of Sox10 of different mobilities are
noted (black and red arrows). Each single ly-
sine mutation eliminates only a single one of
these species.
(D) Western blot showing that mutation of
SUMOylation sites does not affect Sox9 pro-
tein accumulation.
pression (55% increased, n = 47) (Figure 6G). Theselarged otocysts, although staining corresponding to an
increase in cranial glia was also apparent (Figure S3).
To confirm that our findings with Sox9 SUMOylation
mutants were generally applicable to SoxE factors, we
made an analogous set of mutations in Sox10 to create
Sox10K44,333R and Sox10K44,333R/SUMO-1. We found
that the effects of overexpressing these Sox10 SUMO-
ylation mutants closely mimicked the effects of their
Sox9 counterparts (Figure S2).
SUMOylation of SoxE Proteins Is Important
for Inner Ear Development
Given our findings that SoxE proteins could mediate
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box9K61,365R or Sox9K61,365R/SUMO-1 to modulate de-
elopment of this tissue. In contrast to its effects on
eural crest precursor formation, we found that
ox9K61,365R/SUMO-1 increased the size of the otic
lacode, as evidenced by an expanded domain of Pax8
xpression (47% increased, n = 44). Conversely,
ox9K61,365R inhibited Pax8 expression in placodal re-
ions (61% decreased, n = 55) (Figure 6F). Consistent
ith this, when we examined expression of Dlx3 in
he otic vesicle at tailbud stages, we found that
ox9K61,365R inhibited its expression (50% decreased,
= 51), whereas Sox9K61,365R/SUMO-1-injected em-
ryos frequently showed expanded regions of Dlx3 ex-
SoxE SUMOylation during Neural Crest Development
599Figure 6. Regulation of Sox9 Activity by SUMOylation
(A) Schematic showing expressed Sox9 isoforms.
(B) In situ hybridization showing neural crest expression of Sox10 in Sox9- (i), Sox9K61,365R- (ii), and Sox9K61,365R/SUMO-1- (iii) injected em-
bryos.
(C) In situ hybridization showing ectopic Sox10-expressing melanoblasts (black arrows) in stage 28 embryos injected with wild-type Sox9 or
Sox9K61,365R. Sox9K61,365R/SUMO-1-injected embryos never develop ectopic melanoblasts (note absence of these cells in region of red arrows)
but do show increased Sox10 expression in cranial regions (white arrowheads; compare injected and control sides of same embryos).
(D) Close ups of the heads of the swimming tadpoles injected with wild-type Sox9, Sox9K61,365R, or Sox9K61,365R/SUMO-1. Both wild-type
Sox9 and Sox9K61,365R mediate formation of supernumerary differentiated melanocytes on the injected sides of the embryos (red arrowheads),
while Sox9K61,365R/SUMO-1 is unable to do so.
(E) Sox9K61,365R can rescue early (ii) and late (iv) aspects of neural crest formation in Sox10MO-injected embryos (white arrowheads), and
retains its ability to induce ectopic melanocytes (iv, black arrows).
(F) Pax8 expression in the otic placode of stage 13 embryos previously injected with Sox9K61,365R or Sox9K61,365R/SUMO-1.
(G) Dlx3 expression, which marks the otocyst, in stage 28 embryos previously injected with Sox9K61,365R or Sox9K61,365R/SUMO-1.
(H) Table summarizing the effects of Sox9K61,365R and Sox9K61,365R/SUMO-1 in these assays. In panels showing in situ hybridization, light red
or blue stain is the lineage tracer β-gal.
Developmental Cell
600findings underscored that the constitutively SUMO-
ylated form of Sox9 has activities that are distinct from
those possessed by the unmodified protein. Moreover,
our results strongly suggest that the SUMOylation state
of SoxE factors plays a central role in determining
whether these factors will mediate neural crest or otic
placode formation, most likely by regulating their
choice of partner interactions.
Discussion
Work in a number of model organisms has detailed the
expression domains of individual SoxE factors and the
embryonic consequences resulting from the loss of this
expression (reviewed in Hong and Saint-Jeannet, 2005).
By contrast, very little is known about the comparative
activities of these factors. Sox9 and Sox10, together
with Sox8, most likely arose via duplication of a single
ancestral SoxE factor, and the most commonly em-
ployed explanations for the retention of such duplicate
genes during vertebrate evolution are neofunctionaliza-
tion and subfunctionalization. Neofunctionalization as-
sumes that the duplication event frees one copy of the
gene from selective pressure to maintain essential
functions, allowing this copy to evolve new functions.
While examples of neofunctionalization have been re-
ported (McClintock et al., 2001), subfunctionalization
may be a more common explanation for the high reten-
tion rate of duplicate genes. Under the duplication-
degeneration-complementation (DDC) model of sub-
functionalization, the reciprocal loss of aspects of the
ancestral expression pattern in each of the duplicates
could account for the selective pressure to maintain
both copies (Lynch and Force, 2000).
Although Sox9 and Sox10 are initially expressed in all
neural crest precursors in Xenopus, their later expres-
sion is restricted to distinct subsets of neural crest de-
rivatives in all model organisms examined, consistent
with a role for subfunctionalization in retaining these
paralogs subsequent to their duplication. While neo-
functionalization suggests some degree of functional
divergence, duplicate genes maintained as a result of
subfunctionalization are likely to retain similar activities.
To ask whether this is the case for Sox9 and Sox10, we
compared their activities by expressing them in early
Xenopus embryos and assaying their effects on neural
crest and inner ear development. We also compared
their abilities to rescue morpholino-mediated depletion
of Sox10. Significantly, our experiments detected no
differences in the activity of these factors. However, in
the course of this work, we uncovered several pre-
viously unreported activities possessed by these fac-
tors. First, we found that in addition to its previously
described ability to induce the formation of neural crest
progenitor cells, Sox9 can also induce the formation of
both melanocytes and cranial glia (Figure 1), cell types
typically associated with Sox10 function. Most strik-
ingly, we found that both Sox9 and Sox10 were capable
of inducing the formation of enlarged or ectopic ears
(Figure 3).
Because our findings strongly suggested that the
functional activity of SoxE paralogs has been largely
conserved, we sought to determine how these proteins
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oight be regulated such that they can direct the forma-
ion of cell types as distinct as the neural crest and otic
lacode. The identification of UBC9 and SUMO-1 as
oxE-interacting proteins suggested one mechanism
y which the activity of these factors might be regu-
ated posttranslationally, and we confirmed biochemi-
ally that both of these factors undergo SUMOylation
n Xenopus embryos (Figures 4 and 5). While Sox10 can
e modified at two sites, Sox9 is predominantly modi-
ied on a single site in the C terminus (K365), and our
xperiments to date have failed to identify functional
onsequences of mutating the N-terminal SUMO ac-
eptor site of either factor (our unpublished data). While
e cannot rule out that SUMOylation at this site modi-
ies SoxE function in a manner not detected by our as-
ays, in lamprey, the prototype model for the basal ver-
ebrate, all three identified SoxE paralogs have only the
-terminal SUMOylation consensus site (D. McCauley,
ersonal communication), emphasizing the primary im-
ortance of this site.
Although SUMOylation was first described as a post-
ranslational modification almost 10 years ago, the
ellular consequences of SUMO modification remain
oorly understood at the molecular level, and appear
o differ significantly from substrate to substrate. More-
ver, SUMO modification of different sites within the
ame protein can have different consequences for that
rotein’s activity (Poukka et al., 2000; Gill, 2004; Hay,
005). Among the reported effects of SUMOylation on
ranscription factors are the modulation of protein-pro-
ein interactions, protein-DNA interactions, and protein
ocalization, as well as the regulation of protein stability
ia antagonization of ubiquitination (Gill, 2004; Hay,
005). The consequences of SUMOylation for transcrip-
ional activity are also diverse. In a number of cases,
UMO modification of transcriptional activators inhibits
heir potency as activators (Girdwood et al., 2003; Gill,
004); however, SUMO modification of other proteins
eads to an increased ability to activate transcription
Gostissa et al., 1999; Rodriguez et al., 1999; Goodson
t al., 2001; Hong et al., 2001).
The consequences of SUMO modification can also
e highly context dependent. For example, on some
romoters, SUMOylation of Smad4 results in transcrip-
ional repression, while on other promoters this modifi-
ation has been found to enhance Smad4-dependent
ranscriptional activation (Long et al., 2004). Once the
ffects of SUMOylation are better understood, it may
rove to be the case that, like other aspects of tran-
criptional regulation, such promoter context-depen-
ent effects are the rule rather than the exception. In-
eed, given our findings that SoxE isoforms that cannot
e SUMOylated or that mimic a constitutively SUMO-
lated state have distinct effects on neural crest and
tic placode formation, cellular context appears likely
o play an important role in determining SoxE function
n these two cell types.
No direct targets of SoxE transcriptional regulation
ave been identified at early stages of neural crest de-
elopment; however, a number of promoters are known
o be directly regulated by one or more of these factors
uring neural crest differentiation. During melanocyte
evelopment, Sox10 binds the Dct/Trp2 promoter in co-
peration with MITF (Potterf et al., 2001; Ludwig et al.,
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6012004; Murakami and Arnheiter, 2005), whereas during
the development of glia this factor regulates both the
Po and MBP promoters (Peirano et al., 2000; Stolt et
al., 2002, 2004). Similarly, Sox9 binds to and regulates
the Col2a1 promoter during chondrogenesis (Lefebvre
et al., 1997; Tsuda et al., 2003). In all cases where they
have been examined molecularly, SoxE factors have
been shown to function as transcriptional activators on
target promoters. It will therefore be important to deter-
mine how overexpression of constitutively SUMOylated
forms of Sox9 or Sox10 leads to such a dramatic down-
regulation of early neural crest markers such as Sox10
and Slug (Figure 6; Figure S2). An important first step
in this direction will be identification of direct targets of
SoxE regulation during these stages.
Insight into potential mechanisms via which SUMO
modification might regulate SoxE activity may also de-
rive from recent work on MITF. In that study, SUMO
modification of MITF was found to have no effect on
the regulation of promoters containing a single MITF
binding site but suppressed synergistic activation of
promoters with multiple binding sites (Murakami and
Arnheiter, 2005). If SUMOylation regulates SoxE-medi-
ated transcription by selectively modulating coopera-
tive interaction among factors constituting transcrip-
tional complexes, then our findings suggest that distinct
types of complexes may be deployed in tissues such
as the neural crest and the inner ear, and future work
will explore this possibility. Elucidating the precise
mechanisms through which SUMOylation modifies
SoxE activity may have broad implications for under-
standing how developmental regulatory factors with
conserved activity can mediate very different functional
outcomes when expressed in different tissues.
Experimental Procedures
DNA Constructs and Embryo Methods
A partial XSox10 cDNA was isolated from an arrayed cDNA library,
and a full-length clone was generated by 5#RACE (BD Clontech,
Mountain View, CA). XSox9 was isolated from stage 17 cDNA using
low copy number PCR and a high-fidelity polymerase (Tgo; Roche,
Indianapolis, IN). cDNAs were cloned into a pCS2 variant that adds
five C-terminal myc tags (gift of R. Davis) and confirmed by se-
quencing. The Sox9 K61R and K365R mutations and Sox10 K44R
and K333R mutations were generated using the Quick Change
method (Stratagene, La Jolla, CA; primer sequences available upon
request). hSUMO-1 was inserted in the vector pCS2-FlagN and
used for in vivo assays. Sox9K61,365R/SUMO-1 and Sox10K44,333R/
SUMO-1 were created by ligating SUMO-1 in-frame C-terminal to
the full-length Sox9K61,365R or Sox10K44,333R mutants using PCR
methods, inserting a proline and a glycine between the two se-
quences. The fusion proteins were N-terminally epitope tagged by
insertion into vector pCS2-Myc (provided by D. Turner). All con-
structs were confirmed by sequencing. All results shown are repre-
sentative of at least two independent experiments. RNA for injec-
tion was produced in vitro from linearized plasmid templates using
the Message Machine kit (Ambion, Austin, TX). mRNA concentra-
tions injected were in the range of 5–50 pg. Collection, injection,
and in situ hybridization of Xenopus embryos were as described
(Bellmeyer et al., 2003). Sox10 probe is directed against the 3#UTR
of the message and does not recognize the coding region con-
struct used for misexpression experiments. Constructs for making
Pax8 and Dlx3 probes were provided by A. Brandli and T. Moreno,
respectively.
Yeast Two-Hybrid Assays
Sox10 amino acids 1–333 inserted in the vector pEG202 was used
as bait to screen a gastrula stage yeast two-hybrid library in thepJG4-5 vector (gift of S. Sokol) essentially as described (Itoh et
al., 2000). Positive interactors were recovered from yeast, shuttled
through bacteria, and retested in yeast for stringency of interaction
by growth on selective medium and by assaying β-gal activity.
Clones that retested were sequenced, and a number of these were
identified as either Xenopus UBC-9 or Xenopus SUMO-1 (GenBank
accession numbers BC046273 and Z97073, respectively). Baits
consisting of Sox9 amino acids 2–305, Sox9K61R amino acids
2–305, and Sox10K44R amino acids 1–333 were also constructed
in pEG202, and interactions with both SUMO-1 and UBC9 were
compared by plating serial dilutions of the transformants on selec-
tive medium.
Western Blots and SUMOylation Assays
Wild-type or mutant Sox9 or Sox10 proteins were expressed in the
presence or absence of SUMO-1, and embryos were collected at
gastrula stages unless otherwise noted. For Western blots, em-
bryos were lysed in RIPA buffer (50 mM Tris HCl [pH 7.4], 150 mM
NaCl, 1 mM EDTA, 1% Triton X-100, 1% sodium deoxycholate,
0.1% SDS) supplemented with phenylmethylsulfonyl fluoride,
aprotinin, leupeptin, N-ethylmaleimide, cytochalasin B, and 1,10-
phenanthroline. Samples were resolved on SDS-PAGE and proteins
were detected using antibodies against the epitope tags (Myc:
9E10; Santa Cruz Biotechnology, Santa Cruz, CA; Flag: M2; Sigma-
Aldrich, St. Louis, MO). For loading controls, blots were stripped
and reprobed for actin (α-actin; Sigma-Aldrich). Secondary anti-
bodies were horseradish peroxidase coupled and detected by
chemiluminescence (Pierce, Rockford, IL).
Morpholino Oligonucleotide Rescue Experiments
A Sox10 morpholino antisense oligonucleotide designed against
the 5#UTR and coding region of Xenopus Sox10 (5#-AGCTTTGGT
CATCACTCATGGTGCC-3#, Sox10MO) was obtained from Gene
Tools, LLC (Philomath, OR). To deplete Sox10, 10 ng of Sox10MO
was injected into a single blastomere at the eight-cell stage. For
rescues, mRNA encoding epitope-tagged forms of either Sox9,
Sox10, or Sox9K61,365R was subsequently injected, together with
mRNA encoding lineage tracer β-gal. Injected embryos were cul-
tured to the indicated stage, and harvested for in situ hybridization.
Supplemental Data
Supplemental Data include three figures and can be found with this
article online at http://www.developmentalcell.com/cgi/content/
full/9/5/593/DC1/.
Acknowledgments
The authors gratefully acknowledge M. Walker, V. Rao, and J. Lind-
gren for technical assistance, A. Vernon for assistance with West-
ern blots and SUMO assays, and A. Smith for assistance with yeast
assays. We thank L. Hicke, R. Cornell, and members of the labora-
tory for helpful discussions, and S. Sokol, A. Brandli, T. Moreno, C.
Kinter, and L. Hicke for providing reagents. K.M.T. is supported by
a predoctoral fellowship from the NIDCD. This work was supported
by a Basil O’Conner award to C.L., as well as by grants from the
American Cancer Society and the National Institutes of Health. C.L.
is a Scholar of the GM Cancer Research Foundation.
Received: July 13, 2005
Revised: September 2, 2005
Accepted: September 26, 2005
Published: October 31, 2005
References
Aoki, Y., Saint-Germain, N., Gyda, M., Magner-Fink, E., Lee, Y.,
Credidio, C., and Saint-Jeannet, J. (2003). Sox10 regulates the de-
velopment of neural crest-derived melanocytes in Xenopus. Dev.
Biol. 259, 19–33.
Bellmeyer, A., Krase, J., Lindgren, J., and LaBonne, C. (2003). The
protooncogene c-Myc is an essential regulator of neural crest for-
mation in Xenopus. Dev. Cell 4, 827–839.
Developmental Cell
602Bondurand, N., Pingault, V., Goerich, D.E., Lemort, N., Sock, E.,
Caignec, C.L., Wegner, M., and Goossens, M. (2000). Interaction
among SOX10, PAX3 and MITF, three genes altered in Waarden-
burg syndrome. Hum. Mol. Genet. 9, 1907–1917.
Bowles, J., Schepers, G., and Koopman, P. (2000). Phylogeny of
the SOX family of developmental transcription factors based on
sequence and structural indicators. Dev. Biol. 227, 239–255.
Britsch, S., Goerich, D.E., Riethmacher, D., Peirano, R.I., Rossner,
M., Nave, K.A., Birchmeier, C., and Wegner, M. (2001). The tran-
scription factor Sox10 is a key regulator of peripheral glial develop-
ment. Genes Dev. 15, 66–78.
Cheung, M., and Briscoe, J. (2003). Neural crest development is
regulated by the transcription factor Sox9. Development 130,
5681–5693.
Gill, G. (2004). SUMO and ubiquitin in the nucleus: different func-
tions, similar mechanisms? Genes Dev. 18, 2046–2059.
Gilmour, D.T., Maischein, H., and Nüsslein-Volhard, C. (2002). Mi-
gration and function of a glial subtype in the vertebrate peripheral
nervous system. Neuron 34, 577–588.
Girdwood, D., Bumpass, D., Vaughan, O.A., Thain, A., Anderson,
L.A., Snowden, A.W., Garcia-Wilson, E., Perkins, N.D., and Hay, R.T.
(2003). P300 transcriptional repression is mediated by SUMO modi-
fication. Mol. Cell 11, 1043–1054.
Girdwood, D.W.H., Tatham, M.H., and Hay, R.T. (2004). SUMO and
transcriptional regulation. Semin. Cell Dev. Biol. 15, 201–210.
Goodson, M.L., Hong, Y., Rogers, R., Matunis, M.J., Park-Sarge,
O.K., and Sarge, K.D. (2001). Sumo-1 modification regulates the
DNA binding activity of heat shock transcription factor 2, a promy-
elocytic leukemia nuclear body associated transcription factor. J.
Biol. Chem. 276, 18513–18518.
Gostissa, M., Hengstermann, A., Fogal, V., Sandy, P., Schwarz, S.E.,
Scheffner, M., and Del Sal, G. (1999). Activation of p53 by conjuga-
tion to the ubiquitin-like protein SUMO-1. EMBO J. 18, 6462–6471.
Hay, R. (2005). SUMO: a history of modification. Mol. Cell 18, 1–12.
Heller, N., and Brandli, A.W. (1999). Xenopus Pax-2/5/8 or-
thologues: novel insights into Pax gene evolution and identification
of Pax-8 as the earliest marker for otic and pronephric cell lineages.
Dev. Genet. 24, 208–219.
Holmstrom, S., Van Antwerp, M.E., and Iniguez-Lluhi, J.A. (2003).
Direct and distinguishable inhibitory roles for SUMO isoforms in the
control of transcriptional synergy. Proc. Natl. Acad. Sci. USA 100,
15758–15763.
Hong, C.S., and Saint-Jeannet, J.P. (2005). Sox proteins and neural
crest development. Semin. Cell Dev. Biol., in press. Published on-
line July 20, 2005. 10.1016/j.semcdb.2005.06.005.
Hong, Y., Rogers, R., Matunis, M.J., Mayhew, C.N., Goodson, M.L.,
Park-Sarge, O.K., and Sarge, K.D. (2001). Regulation of heat shock
transcription factor 1 by stress-induced SUMO-1 modification. J.
Biol. Chem. 276, 40263–40267.
Honore, S.M., Aybar, M.J., and Mayor, R. (2003). Sox10 is required
for the early development of the prospective neural crest in Xeno-
pus embryos. Dev. Biol. 260, 79–96.
Itoh, K., Antipova, A., Ratcliffe, M.J., and Sokol, S. (2000). Interac-
tion of dishevelled and Xenopus axin-related protein is required for
wnt signal transduction. Mol. Cell. Biol. 20, 2228–2238.
Kamachi, Y., Uchikawa, M., and Kondoh, H. (2000). Pairing SOX off:
with partners in the regulation of embryonic development. Trends
Genet. 16, 182–187.
Kelsh, R.N., Dutton, K., Medlin, J., and Eisen, J.S. (2000). Expres-
sion of zebrafish fkd6 in neural crest-derived glia. Mech. Dev. 93,
161–164.
Kim, J., Lo, L., Dormand, E., and Anderson, D.J. (2003). SOX10
maintains multipotency and inhibits neuronal differentiation of neu-
ral crest stem cells. Neuron 38, 17–31.
Komatsu, T., Mizusaki, M., Mukai, T., Ogawa, H., Baba, D., Shira-
kawa, M., Hatakeyama, S., Nakayama, K., Yamamoto, H., Kikuchi, A.,
and Morohashi, K. (2004). Small ubiquitin-like modifier 1 (SUMO-1)
modification of the synergy control motif of Ad4 binding protein/
steroidogenic factor 1 (Ad4BP/SF-1) regulates synergistic tran-
s
2
L
t
M
L
S
a
2
L
C
c
B
L
a
d
t
L
o
J
L
c
e
F
L
p
M
C
v
m
M
t
m
P
S
i
3
P
(
s
P
H
i
d
2
P
C
l
1
R
a
t
R
t
s
S
J
S
S
t
m
S
S
f
4
S
S
e
scription between Ad4BP/SF-1 and Sox9. Mol. Endocrinol. 18,
451–2462.
ang, D., and Epstein, J.A. (2003). Sox10 and Pax3 physically in-
eract to mediate activation of a conserved c-RET enhancer. Hum.
ol. Genet. 12, 937–945.
ee, Y.H., Aoki, Y., Hong, C.S., Saint-Germain, N., Credidio, C., and
aint-Jeannet, J.P. (2004). Early requirement of the transcriptional
ctivator Sox9 for neural crest specification in Xenopus. Dev. Biol.
75, 93–103.
efebvre, V., Huang, W., Harley, V.R., Goodfellow, P.N., and de
rombrugghe, B. (1997). SOX9 is a potent activator of the chondro-
yte-specific enhancer of the Proα1 (II) collagen gene. Mol. Cell.
iol. 17, 2336–2346.
iu, D., Chu, H., Maves, L., Yan, Y., Morcos, P.A., Postlethwait, J.H.,
nd Westerfield, M. (2003). Fgf3 and Fgf8 dependent and indepen-
ent transcription factors are required for otic placode specifica-
ion. Development 130, 2213–2224.
ong, J., Wang, G., Dongming, H.E., and Lui, F. (2004). Repression
f Smad4 transcriptional activity by SUMO modification. Biochem.
. 379, 23–29.
udwig, A., Rehberg, S., and Wegner, M. (2004). Melanocyte-spe-
ific expression of dopachrome tautomerase is dependent on syn-
rgistic gene activation by the Sox10 and Mitf transcription factors.
EBS Lett. 556, 236–244.
ynch, M., and Force, A. (2000). The probability of duplicate gene
reservation by subfunctionalization. Genetics 154, 459–473.
cClintock, J.M., Carlson, R., Mann, D.M., and Prince, V.E. (2001).
onsequences of Hox gene duplication in the vertebrates: an in-
estigation of the zebrafish Hox paralogue group 1 genes. Develop-
ent 128, 2471–2484.
urakami, H., and Arnheiter, H. (2005). Sumoylation modulates
ranscriptional activity of MITF in a promoter-specific manner. Pig-
ent Cell Res. 18, 265–277.
aratore, C., Eichenberger, C., Suter, U., and Sommer, L. (2002).
ox10 haploinsufficiency affects maintenance of progenitor cells
n a mouse model of Hirschsprung disease. Hum. Mol. Genet. 11,
075–3085.
eirano, R.I., Goerich, D.E., Riethmacher, D., and Wegner, M.
2000). Protein zero gene expression is regulated by the glial tran-
cription factor Sox10. Mol. Cell. Biol. 20, 3198–3209.
otterf, S.B., Mallaaghababa, R., Hou, L., Southard-Smith, E.M.,
ornyak, H.A., and Paven, W.J. (2001). Analysis of SOX10 function
n neural crest-derived melanocyte development: SOX10-depen-
ent transcriptional control of dopachrome tautomerase. Dev. Biol.
37, 245–257.
oukka, H., Karvonen, U., Janne, O.A., and Palvimo, J.J. (2000).
ovalent modification of the androgen receptor by small ubiquitin-
ike modifier 1 (SUMO-1). Proc. Natl. Acad. Sci. USA 97, 14145–
4150.
odriguez, M.S., Desterro, J.M., Lain, S., Midgley, C.A., Lane, D.P.,
nd Hay, R.T. (1999). SUMO-1 modification activates the transcrip-
ional response of p53. EMBO J. 18, 6455–6461.
oss, S., Best, J.L., Zon, L.I., and Gill, G. (2002). SUMO-1 modifica-
ion represses Sp3 transcriptional activation and modulates its
ubnuclear localization. Mol. Cell 10, 831–842.
aint-Germain, N., Lee, Y., Zhang, Y., Sargent, T.D., and Saint-
eannet, J. (2004). Specification of the otic placode depends on
ox9 function in Xenopus. Development 131, 1755–1763.
outhard-Smith, E.M., Kos, L., and Pavan, W.J. (1998). Sox10 muta-
ion disrupts neural crest development in Dom Hirschsprung
ouse model. Nat. Genet. 18, 60–64.
pokony, R.F., Aoki, Y., Saint-Germain, N., Magner-Fink, E., and
aint-Jeannet, J. (2002). The transcription factor Sox9 is required
or cranial neural crest development in Xenopus. Development 129,
21–432.
tolt, C.C., Rehberg, S., Ader, M., Lommes, P., Riethmacher, D.,
chachner, M., Bartsch, U., and Wegner, M. (2002). Terminal differ-
ntiation of myelin-forming oligodendrocytes depends on the tran-
cription factor Sox10. Genes Dev. 16, 165–170.
SoxE SUMOylation during Neural Crest Development
603Stolt, C.C., Lommes, P., Friedrich, R.P., and Wegner, M. (2004).
Transcription factors Sox8 and Sox10 perform non-equivalent roles
during oligodendrocyte development despite functional redun-
dancy. Development 131, 2349–2358.
Tsuda, M., Takahashi, S., Takahashi, Y., and Asahara, H. (2003).
Transcriptional co-activators CREB-binding protein and p300 regu-
late chondrocyte-specific gene expression via association with
Sox9. J. Biol. Chem. 278, 27224–27229.
Watanabe, K., Takeda, K., Katori, Y., Ikeda, K., Oshima, T., Yasu-
moto, K., Saito, H., Takasaka, T., and Shibahara, S. (2000). Expres-
sion of the Sox10 gene during mouse inner ear development. Brain
Res. Mol. Brain Res. 84, 141–145.
Wegner, M. (1999). From head to toes: the multiple facets of Sox
proteins. Nucleic Acids Res. 27, 1409–1420.
